NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NYSE · ELAN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Elanco Animal Health Incorporated’s quoted price sits in the lower half of its reported 52-week range, 16.94% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Elanco Animal Health Incorporated’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of $0.20. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Elanco Animal Health Incorporated’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | $0.37+19.35% vs estimate | $1.19B+1.28% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | $0.14-12.5% vs estimate | $1.02B-15.7% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | $0.13+8.33% vs estimate | $1.03B+1.68% vs estimate |
|---|
THE ANALYST VIEW
22 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $26.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
$575.98+$13.07 (+2.32%)
IDEXX Laboratories, Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.2% below the high.
$78.80+$1.00 (+1.29%)
Zoetis Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.67% below the high.
€98.40+€2.45 (+2.55%)
Orion Oyj’s quoted price sits in the upper half of its reported 52-week range, 1.2% below the high.
$12.26+$0.14 (+1.16%)
Neogen Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.03% below the high.
$38.86+$0.98 (+2.59%)
Phibro Animal Health Corporation’s quoted price sits in the lower half of its reported 52-week range, 35.32% below the high.
